Lumbricus protein peptide polypeptide tablet with functions of dissolving thrombus and protecting blood vessels

Abstract

The invention belongs to the technical field of medicines and health-care products, and discloses an earthworm protein peptide polypeptide tablet with functions of dissolving thrombus and protecting blood vessels. Comprising the following components in parts by mass: 20 to 50 parts of earthworm protein peptide, 30 to 40 parts of sorbitol, 2 to 5 parts of lactose, 2 to 10 parts of freeze-dried natto powder, 2 to 10 parts of rice bran fatty alkanol, 1 to 5 parts of dunaliella salina powder, 1 to 5 parts of bovine myocardial peptide powder, 0.01 to 0.05 part of collagen peptide, 0.01 to 0.05 part of soybean peptide powder, 0.01 to 0.05 part of vitamin B6, 0.04 to 0.12 part of a compound nutrition enhancer, 1 to 5 parts of fructo-oligosaccharide, 0.01 to 0.05 part of magnesium stearate and 0.04 to 0.012 part of a compound coating agent. The earthworm protein peptide polypeptide tablet has the effects of thrombolysis and blood fat reduction, can assist in preventing thrombosis, regulating blood fat metabolism and assisting in reducing cholesterol, and has an antioxidant function.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines and health products, and in particular relates to an earthworm protein peptide polypeptide tablet with the functions of dissolving thrombus and protecting blood vessels. Background Art

[0002] Cardiovascular and cerebrovascular diseases are among the diseases with the highest morbidity and mortality in the world. For example, stroke, myocardial infarction, atherosclerosis, etc., their pathological basis is mostly related to thrombosis, vascular endothelial damage and inflammatory response. At present, commonly used antithrombotic drugs in clinical practice include antiplatelet drugs (such as aspirin, clopidogrel), anticoagulants (such as heparin, warfarin) and thrombolytic drugs (such as tissue plasminogen activator t-PA). However, traditional drugs have the following limitations: 1. Significant side effects. Long-term use of antiplatelet or anticoagulant drugs may lead to increased bleeding risk, gastrointestinal damage and other problems. 2. Short half-life. Thrombolytic drugs (such as t-PA) need to be injected intravenously and have a short half-life, and the treatment window is narrow. 3. Insufficient targeting. Existing drugs mostly target a single pathological link, such as inhibiting platelet aggregation or dissolving fibrin, and it is difficult to repair vascular endothelial damage or inhibit inflammatory response at the same time.

[0003] Therefore, how to obtain a earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions is a technical problem that needs to be solved urgently by those skilled in the art. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions, which is prepared by mixing a reasonable amount of earthworm protein peptide, sorbitol, lactose, natto freeze-dried powder, bovine myocardial peptide powder, collagen peptide, soybean peptide powder, vitamin B 6 The compounding is carried out to obtain earthworm protein peptide polypeptide tablets, which improves the bioavailability of the earthworm protein peptide polypeptide tablets and has the effects of dissolving blood clots and protecting blood vessels.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The invention provides a thrombolytic and vascular protective earthworm protein peptide polypeptide tablet, characterized in that it comprises the following components in parts by weight: 20 to 50 parts of earthworm protein peptide, 30 to 40 parts of sorbitol, 2 to 5 parts of lactose, 2 to 10 parts of natto freeze-dried powder, 2 to 10 parts of rice bran fatty alkyl alcohol, 1 to 5 parts of salt algae powder, 1 to 5 parts of bovine myocardial peptide powder, 0.01 to 0.05 parts of collagen peptide, 0.01 to 0.05 parts of soybean peptide powder, and vitamin B1 6 0.01-0.05 parts, compound nutritional enhancer 0.04-0.12 parts, oligofructose 1-5 parts, magnesium stearate 0.01-0.05 parts, compound coating agent 0.04-0.012 parts.

[0007] Preferably, the compound nutritional enhancer includes vitamin B 12 0.01-0.03 parts, 0.01-0.03 parts of citric acid, 0.01-0.03 parts of sodium citrate, and 0.01-0.03 parts of maltodextrin.

[0008] Preferably, the compound coating agent comprises, in parts by mass, 0.01 to 0.03 parts of hydroxypropyl methylcellulose, 0.01 to 0.03 parts of titanium dioxide, 0.01 to 0.03 parts of polyethylene glycol and 0.01 to 0.03 parts of magnesium stearate.

[0009] Preferably, the mass ratio of the earthworm protein peptide to sorbitol is 1:1-2; the mass ratio of the earthworm protein peptide to lactose is 1:0.1-0.3; the mass ratio of the earthworm protein peptide to natto freeze-dried powder is 1:0.1-0.5; the mass ratio of the earthworm protein peptide to rice bran fatty alkanol is 1:0.1-0.5.

[0010] Preferably, the mass ratio of the earthworm protein peptide to the salt algae powder is 1:0.02-0.2; the mass ratio of the earthworm protein peptide to the bovine myocardial peptide powder is 1:0.02-0.2.

[0011] Preferably, the earthworm protein peptide polypeptide tablets include the following components in parts by weight: 32 parts of earthworm protein peptide, 35 parts of sorbitol, 3 parts of lactose, 5 parts of natto freeze-dried powder, 5 parts of rice bran fatty alkyl alcohol, 2 parts of salt algae powder, 1.5 parts of bovine myocardial peptide powder, 0.01 parts of collagen peptide, 0.01 parts of soybean peptide powder, and vitamin B 6 0.01 parts, 0.04 parts of compound nutritional enhancers, 2 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.05 parts of compound coating agents.

[0012] The beneficial effects of the present invention are:

[0013] 1) The present invention comprises earthworm protein peptide, natto freeze-dried powder, salt algae powder, and soybean peptide powder, which can directly dissolve blood clots by degrading fibrin, and at the same time regulate the plasminogen activator system, have thrombolytic and blood lipid lowering effects, can assist in preventing thrombosis, and reasonably control the contents of earthworm protein peptide, sorbitol, lactose, natto freeze-dried powder, rice bran fatty alkyl alcohol, salt algae powder, bovine myocardial peptide powder, collagen peptide, and soybean peptide powder to prepare earthworm protein peptide polypeptide tablets; the invention can regulate blood lipid metabolism, assist in lowering cholesterol, and have antioxidant function.

[0014] 2) Vitamin B 6, compound nutritional enhancers, oligofructose, magnesium stearate, and compound coating agents are used in combination to improve the oral compliance of earthworm protein peptide polypeptide tablets, make the product taste good, have no peculiar smell, and have high bioavailability of effective drugs; and salt algae powder is a good antioxidant, which enhances anti-inflammatory and immune capabilities. DETAILED DESCRIPTION

[0015] The invention provides a lumbar protein peptide polypeptide tablet with thrombolytic and vascular protection functions, comprising the following components in parts by weight: 20-50 parts of lumbar protein peptide, 30-40 parts of sorbitol, 2-5 parts of lactose, 2-10 parts of natto freeze-dried powder, 2-10 parts of rice bran fatty alkyl alcohol, 1-5 parts of salt algae powder, 1-5 parts of bovine myocardial peptide powder, 0.01-0.05 parts of collagen peptide, 0.01-0.05 parts of soybean peptide powder, and vitamin B12. 6 0.01-0.05 parts, compound nutritional enhancer 0.04-0.12 parts, oligofructose 1-5 parts, magnesium stearate 0.01-0.05 parts, compound coating agent 0.04-0.012 parts.

[0016] The earthworm protein peptide polypeptide tablets of the present invention contain 20 to 50 parts of earthworm protein peptides, preferably 25 to 45 parts, more preferably 30 to 40 parts, and more preferably 32 to 38 parts.

[0017] As a traditional Chinese medicine, the extract of earthworm protein peptide has been proven to have fibrinolytic activity. Earthworms are rich in fibrinolytic enzymes (such as lumbrokinase), which can directly dissolve blood clots by degrading fibrin and regulate the plasminogen activator system. After enzymatic hydrolysis, earthworm protein can generate small molecule active peptides, which have the advantage of high bioavailability: small molecule peptides are easily absorbed by the intestine, overcoming the defect of low oral activity of traditional extracts. Multi-target action: Some peptides not only have thrombolytic activity, but also can protect vascular endothelial cells through antioxidant and anti-inflammatory mechanisms.

[0018] The earthworm protein peptide polypeptide tablets of the present invention contain 30 to 40 parts of sorbitol, preferably 32 to 38 parts, more preferably 33 to 37 parts, and even more preferably 34 to 36 parts.

[0019] The earthworm protein peptide polypeptide tablets of the present invention contain 2 to 5 parts of lactose, preferably 2.5 to 4.5 parts, more preferably 3 to 4 parts, and more preferably 3.2 to 3.8 parts.

[0020] The earthworm protein peptide polypeptide tablets of the present invention contain 2 to 10 parts of natto freeze-dried powder, preferably 3 to 9 parts, further preferably 4 to 8 parts, and more preferably 5 to 7 parts. The natto freeze-dried powder contains nattokinase, has thrombolytic and lipid-lowering effects, and may assist in preventing thrombosis.

[0021] The earthworm protein peptide polypeptide tablets of the present invention contain 2 to 10 parts of rice bran fatty alkanols, preferably 3 to 9 parts, more preferably 4 to 8 parts, and more preferably 5 to 7 parts. The rice bran fatty alkanols are extracted from rice bran oil, can regulate blood lipid metabolism, assist in lowering cholesterol, and have antioxidant function.

[0022] The earthworm protein peptide polypeptide tablets of the present invention contain 1 to 5 parts of salt algae powder, preferably 1.5 to 4.5 parts, more preferably 2 to 4 parts, and more preferably 2.5 to 3.5 parts. The salt algae powder is rich in natural β-carotene, minerals and antioxidants, which may support the immune system and anti-inflammatory.

[0023] The earthworm protein peptide polypeptide tablets of the present invention contain 1 to 5 parts of bovine myocardial peptide, preferably 1.5 to 4.5 parts, more preferably 2 to 4 parts, and more preferably 2.5 to 3.5 parts. Bovine myocardial peptide contains myocardial cell active peptides, which can help improve myocardial metabolism or cardiovascular function.

[0024] The earthworm protein peptide polypeptide tablets of the present invention contain 0.01 to 0.05 parts of collagen peptide, preferably 0.015 to 0.045 parts, more preferably 0.02 to 0.04 parts, and more preferably 0.025 to 0.035 parts.

[0025] The earthworm protein peptide polypeptide tablets of the present invention contain 0.01 to 0.05 parts of soybean peptide powder, preferably 0.015 to 0.045 parts, further preferably 0.02 to 0.04 parts, and more preferably 0.025 to 0.035 parts. Soybean peptide powder is an easily absorbed small molecule peptide that may assist in lowering blood pressure, regulating blood lipids, and promoting protein synthesis.

[0026] The earthworm protein peptide polypeptide tablets of the present invention contain 0.01 to 0.05 portions of vitamin B 6 , preferably 0.015 to 0.045 parts, more preferably 0.02 to 0.04 parts, more preferably 0.025 to 0.035 parts, vitamin B 6 It participates in amino acid metabolism, hemoglobin synthesis and neurotransmitter production, and supports energy metabolism.

[0027] The earthworm protein peptide polypeptide tablets of the present invention contain 0.04 to 0.12 parts of a compound nutritional enhancer, preferably 0.05 to 0.11 parts, more preferably 0.06 to 0.10 parts, and more preferably 0.07 to 0.09 parts.

[0028] The earthworm protein peptide polypeptide tablets of the present invention contain 1 to 5 parts of oligofructose, preferably 1.5 to 4.5 parts, more preferably 2 to 4 parts, and more preferably 2.5 to 3.5 parts.

[0029] The earthworm protein peptide polypeptide tablets of the present invention contain 0.01 to 0.05 parts of magnesium stearate, preferably 0.015 to 0.045 parts, more preferably 0.02 to 0.04 parts, and even more preferably 0.025 to 0.035 parts.

[0030] The earthworm protein peptide polypeptide tablets of the present invention contain 0.04 to 0.12 parts of the compound coating agent, preferably 0.05 to 0.11 parts, more preferably 0.06 to 0.10 parts, and more preferably 0.07 to 0.09 parts.

[0031] In the present invention, the compound nutritional enhancer includes vitamin B 12 0.01-0.03 parts, 0.01-0.03 parts of citric acid, 0.01-0.03 parts of sodium citrate, and 0.01-0.03 parts of maltodextrin.

[0032] The compound nutritional enhancer of the present invention contains 0.01 to 0.03 parts of vitamin B 12 0.01 to 0.03 parts, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and even more preferably 0.018 to 0.023 parts.

[0033] The compound nutritional enhancer of the present invention comprises 0.01 to 0.03 parts of citric acid, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and more preferably 0.018 to 0.023 parts.

[0034] The compound nutritional enhancer of the present invention comprises 0.01 to 0.03 parts of sodium citrate, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and more preferably 0.018 to 0.023 parts.

[0035] The compound nutritional enhancer of the present invention comprises 0.01 to 0.03 parts of maltodextrin, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and more preferably 0.018 to 0.023 parts.

[0036] In the present invention, the compound coating agent comprises 0.01 to 0.03 parts of hydroxypropyl methylcellulose, 0.01 to 0.03 parts of titanium dioxide, 0.01 to 0.03 parts of polyethylene glycol and 0.01 to 0.03 parts of magnesium stearate in parts by mass.

[0037] The composite film coating agent of the present invention contains 0.01 to 0.03 parts of hydroxypropyl methylcellulose, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and even more preferably 0.018 to 0.023 parts.

[0038] The composite coating agent of the present invention contains 0.01 to 0.03 parts of titanium dioxide, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and even more preferably 0.018 to 0.023 parts.

[0039] The composite coating agent of the present invention contains 0.01 to 0.03 parts of polyethylene glycol, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and even more preferably 0.018 to 0.023 parts.

[0040] The composite coating agent of the present invention contains 0.01 to 0.03 parts of magnesium stearate, preferably 0.012 to 0.028 parts, more preferably 0.015 to 0.025 parts, and more preferably 0.018 to 0.023 parts.

[0041] In the present invention, the mass ratio of the earthworm protein peptide to sorbitol is 1:1-2, preferably 1:1.1-1.9, more preferably 1:1.2-1.8, and more preferably 1:1.3-1.7.

[0042] In the present invention, the mass ratio of the earthworm protein peptide to lactose is 1:0.1-0.3, preferably 1:0.11-0.28, further preferably 1:0.015-0.025, and more preferably 1:0.018-0.020.

[0043] In the present invention, the mass ratio of the earthworm protein peptide to the natto freeze-dried powder is 1:0.1-0.5, preferably 1:0.15-0.45, further preferably 1:0.2-0.4, and more preferably 1:0.25-0.35.

[0044] In the present invention, the mass ratio of the earthworm protein peptide to rice bran fatty alkanol is 1:0.1-0.5, preferably 1:0.15-0.45, further preferably 1:0.2-0.4, and more preferably 1:0.25-0.35.

[0045] In the present invention, the mass ratio of the earthworm protein peptide to the salt algae powder is 1:0.02-0.2, preferably 1:0.05-0.18, further preferably 1:0.08-0.15, and more preferably 1:0.1-0.13.

[0046] In the present invention, the mass ratio of the earthworm protein peptide to the bovine myocardial peptide powder is 1:0.02-0.2, preferably 1:0.05-0.18, further preferably 1:0.08-0.15, and more preferably 1:0.1-0.13.

[0047] In the present invention, the following components are included in parts by weight: 32 parts of earthworm protein peptide, 35 parts of sorbitol, 3 parts of lactose, 5 parts of natto freeze-dried powder, 5 parts of rice bran fatty alkyl alcohol, 2 parts of salt algae powder, 1.5 parts of bovine myocardial peptide powder, 0.01 parts of collagen peptide, 0.01 parts of soybean peptide powder, and vitamin B 6 0.01 parts, 0.04 parts of compound nutritional enhancers, 2 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.05 parts of compound coating agents.

[0048] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0049] Example 1

[0050] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 21 parts of earthworm protein peptide, 32 parts of sorbitol, 2 parts of lactose, 3 parts of natto freeze-dried powder, 3 parts of rice bran fatty alkyl alcohol, 2 parts of salt algae powder, 2 parts of bovine myocardial peptide powder, 0.01 parts of collagen peptide, 0.02 parts of soybean peptide powder, and vitamin B 6 0.01 parts, 0.06 parts of compound nutritional enhancers, 2 parts of oligofructose, 0.02 parts of magnesium stearate, and 0.05 parts of compound coating agents.

[0051] The compound nutritional enhancer includes vitamin B 12 0.02 parts, citric acid 0.01 parts, sodium citrate 0.01 parts, maltodextrin 0.02 parts. The composite coating agent includes 0.01 parts of hydroxypropyl methylcellulose, 0.01 parts of titanium dioxide, 0.02 parts of polyethylene glycol and 0.01 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0052] Example 2

[0053] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 25 parts of earthworm protein peptide, 33 parts of sorbitol, 3 parts of lactose, 5 parts of natto freeze-dried powder, 5 parts of rice bran fatty alkyl alcohol, 2 parts of salt algae powder, 2 parts of bovine myocardial peptide powder, 0.02 parts of collagen peptide, 0.03 parts of soybean peptide powder, and vitamin B 6 0.03 parts, 0.08 parts of compound nutritional enhancers, 3 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.10 parts of compound coating agents.

[0054] The compound nutritional enhancer includes vitamin B 120.02 parts, citric acid 0.01 parts, sodium citrate 0.03 parts, maltodextrin 0.02 parts. The composite coating agent includes 0.02 parts of hydroxypropyl methylcellulose, 0.02 parts of titanium dioxide, 0.03 parts of polyethylene glycol and 0.03 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0055] Example 3

[0056] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 35 parts of earthworm protein peptide, 35 parts of sorbitol, 5 parts of lactose, 8 parts of natto freeze-dried powder, 8 parts of rice bran fatty alkyl alcohol, 3 parts of salt algae powder, 3 parts of bovine myocardial peptide powder, 0.03 parts of collagen peptide, 0.03 parts of soybean peptide powder, and vitamin B 6 0.03 parts, 0.12 parts of compound nutritional enhancers, 3 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.10 parts of compound coating agents.

[0057] The compound nutritional enhancer includes vitamin B 12 0.03 parts, citric acid 0.04 parts, sodium citrate 0.03 parts, maltodextrin 0.02 parts. The composite coating agent includes 0.02 parts of hydroxypropyl methylcellulose, 0.02 parts of titanium dioxide, 0.03 parts of polyethylene glycol and 0.03 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0058] Example 4

[0059] A lumbar protein peptide polypeptide tablet with thrombolytic and vascular protection functions comprises the following raw materials in parts by weight: 38 parts of lumbar protein peptide, 35 parts of sorbitol, 3 parts of lactose, 8 parts of natto freeze-dried powder, 8 parts of rice bran fatty alkyl alcohol, 3 parts of salt algae powder, 3 parts of bovine myocardial peptide powder, 0.02 parts of collagen peptide, 0.03 parts of soybean peptide powder, 0.03 parts of vitamin B6, 0.08 parts of compound nutritional enhancer, 1 part of oligofructose, 0.03 parts of magnesium stearate, and 0.10 parts of compound coating agent.

[0060] The compound nutritional enhancer includes vitamin B 12 0.03 parts, citric acid 0.01 parts, sodium citrate 0.02 parts, maltodextrin 0.02 parts. The composite coating agent includes 0.02 parts of hydroxypropyl methylcellulose, 0.02 parts of titanium dioxide, 0.03 parts of polyethylene glycol and 0.03 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0061] Example 5

[0062] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 32 parts of earthworm protein peptide, 35 parts of sorbitol, 3 parts of lactose, 5 parts of natto freeze-dried powder, 5 parts of rice bran fatty alkyl alcohol, 2 parts of salt algae powder, 1.5 parts of bovine myocardial peptide powder, 0.01 parts of collagen peptide, 0.01 parts of soybean peptide powder, and vitamin B 6 0.01 parts, 0.04 parts of compound nutritional enhancers, 2 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.05 parts of compound coating agents.

[0063] The compound nutritional enhancer includes vitamin B 12 0.01 part, citric acid 0.01 part, sodium citrate 0.01 part, maltodextrin 0.01 part. The composite coating agent includes 0.01 part of hydroxypropyl methylcellulose, 0.02 part of titanium dioxide, 0.01 part of polyethylene glycol and 0.01 part of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0064] Example 6

[0065] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 45 parts of earthworm protein peptide, 35 parts of sorbitol, 3 parts of lactose, 10 parts of natto freeze-dried powder, 5 parts of rice bran fatty alkyl alcohol, 3 parts of salt algae powder, 3 parts of bovine myocardial peptide powder, 0.05 parts of collagen peptide, 0.05 parts of soybean peptide powder, and vitamin B 6 0.03 parts, 0.06 parts of compound nutritional enhancers, 3 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.06 parts of compound coating agents.

[0066] The compound nutritional enhancer includes vitamin B 12 0.03 parts, citric acid 0.01 parts, sodium citrate 0.01 parts, maltodextrin 0.01 parts. The composite coating agent includes 0.02 parts of hydroxypropyl methylcellulose, 0.02 parts of titanium dioxide, 0.01 parts of polyethylene glycol and 0.01 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0067] Example 7

[0068] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 46 parts of earthworm protein peptide, 36 parts of sorbitol, 3 parts of lactose, 8 parts of natto freeze-dried powder, 6 parts of rice bran fatty alkyl alcohol, 3 parts of salt algae powder, 3 parts of bovine myocardial peptide powder, 0.03 parts of collagen peptide, 0.02 parts of soybean peptide powder, and vitamin B 6 0.03 parts, 0.012 parts of compound nutritional enhancers, 4 parts of oligofructose, 0.04 parts of magnesium stearate, and 0.012 parts of compound coating agents.

[0069] The compound nutritional enhancer includes vitamin B 12 0.02 parts, citric acid 0.04 parts, sodium citrate 0.03 parts, maltodextrin 0.03 parts. The composite coating agent includes 0.03 parts of hydroxypropyl methylcellulose, 0.02 parts of titanium dioxide, 0.04 parts of polyethylene glycol and 0.03 parts of magnesium stearate in parts by weight, and the above raw materials in parts by weight are mixed and compressed into tablets.

[0070] Example 8

[0071] A thrombolytic and vascular protective earthworm protein peptide polypeptide tablet comprises the following raw materials in parts by weight: 30 parts of earthworm protein peptide, 30 parts of sorbitol, 2 parts of lactose, 2 parts of natto freeze-dried powder, 3 parts of rice bran fatty alkyl alcohol, 3 parts of salt algae powder, 3 parts of bovine myocardial peptide powder, 0.05 parts of collagen peptide, 0.05 parts of soybean peptide powder, and vitamin B 6 0.05 parts, 0.10 parts of compound nutritional enhancers, 3 parts of oligofructose, 0.03 parts of magnesium stearate, and 0.08 parts of compound coating agent.

[0072] The compound nutritional enhancer includes vitamin B 12 0.02 parts, citric acid 0.05 parts, sodium citrate 0.01 parts, maltodextrin 0.02 parts. The composite coating agent includes 0.01 parts of hydroxypropyl methylcellulose, 0.01 parts of titanium dioxide, 0.03 parts of polyethylene glycol and 0.03 parts of magnesium stearate in parts by weight. The above raw materials in parts by weight are mixed and compressed into tablets.

[0073] The present invention comprises earthworm protein peptide, natto freeze-dried powder, salt algae powder, and soybean peptide powder, which can directly dissolve blood clots by degrading fibrin, and at the same time regulate the plasminogen activator system, have thrombolytic and blood lipid lowering effects, can assist in preventing thrombosis, and reasonably control the contents of earthworm protein peptide, sorbitol, lactose, natto freeze-dried powder, rice bran fatty alkyl alcohol, salt algae powder, bovine myocardial peptide powder, collagen peptide, and soybean peptide powder to prepare earthworm protein peptide polypeptide tablets; can regulate blood lipid metabolism, assist in lowering cholesterol, and have antioxidant function. Vitamin B 6 , compound nutritional enhancers, oligofructose, magnesium stearate, and compound coating agents are used in combination to improve the oral compliance of earthworm protein peptide polypeptide tablets, make the product taste good, have no peculiar smell, and have high bioavailability of effective drugs; and salt algae powder is a good antioxidant, which enhances anti-inflammatory and immune capabilities.

[0074] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A lumbar protein peptide polypeptide tablet having the function of dissolving blood clots and protecting blood vessels, characterized in that: The invention comprises the following components in parts by mass: 20-50 parts of earthworm protein peptide, 30-40 parts of sorbitol, 2-5 parts of lactose, 2-10 parts of natto freeze-dried powder, 2-10 parts of rice bran fatty alkanol, 1-5 parts of salt algae powder, 1-5 parts of bovine myocardial peptide powder, 0.01-0.05 parts of collagen peptide, 0.01-0.05 parts of soybean peptide powder, 0.01-0.05 parts of vitamin B6, 0.04-0.12 parts of compound nutritional enhancer, 1-5 parts of oligofructose, 0.01-0.05 parts of magnesium stearate and 0.04-0.012 parts of compound coating agent.

2. The earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions according to claim 1, characterized in that: The compound nutritional enhancer includes vitamin B 12 0.01-0.03 parts, citric acid 0.01-0.03 parts, sodium citrate 0.01-0.03 parts, maltodextrin 0.01-0.03 parts.

3. The earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions according to claim 1, characterized in that: The compound coating agent comprises, by weight, 0.01 to 0.03 parts of hydroxypropyl methylcellulose, 0.01 to 0.03 parts of titanium dioxide, 0.01 to 0.03 parts of polyethylene glycol and 0.01 to 0.03 parts of magnesium stearate.

4. The earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions according to claim 1, characterized in that: The mass ratio of the earthworm protein peptide to sorbitol is 1:1-2; the mass ratio of the earthworm protein peptide to lactose is 1:0.1-0.3; the mass ratio of the earthworm protein peptide to natto freeze-dried powder is 1:0.1-0.5; the mass ratio of the earthworm protein peptide to rice bran fatty alkanol is 1:0.1-0.

5.

5. The earthworm protein peptide polypeptide tablet with thrombolytic and vascular protection functions according to claim 4, characterized in that: The mass ratio of the earthworm protein peptide to the salt algae powder is 1:0.02-0.2; the mass ratio of the earthworm protein peptide to the bovine myocardial peptide powder is 1:0.02-0.

2.

6. The earthworm protein peptide polypeptide tablet having thrombolytic and vascular protection functions according to any one of claims 1 to 5, characterized in that: The invention comprises the following components in parts by mass: 32 parts of earthworm protein peptide, 35 parts of sorbitol, 3 parts of lactose, 5 parts of freeze-dried natto powder, 5 parts of rice bran fatty alkanol, 2 parts of salt algae powder, 1.5 parts of bovine myocardial peptide powder, 0.01 parts of collagen peptide, 0.01 parts of soybean peptide powder, 0.01 parts of vitamin B6, 0.04 parts of compound nutritional enhancer, 2 parts of oligofructose, 0.03 parts of magnesium stearate and 0.05 parts of compound coating agent.